Bluejay Diagnostics (BJDX) deepens Sanyoseiko partnership for Symphony platform
Rhea-AI Filing Summary
Bluejay Diagnostics, Inc. entered into an amendment on October 3, 2025 to its existing Master Service Agreement and Master Supply Agreement with Sanyoseiko Co., Ltd.. The change is tied to Bluejay’s commercialization of its Symphony platform, a near-patient testing system designed to provide rapid results for biomarkers such as IL-6 used in sepsis management.
Under the amended arrangements, Sanyoseiko will provide end-to-end support for the Symphony platform. This includes supporting redevelopment of analyzers and cartridges with hardware, software, and design updates, managing raw material sourcing and vendor compliance, and acting as Bluejay’s contract manufacturer for analyzers, cartridges, and related components. Sanyoseiko will also handle fulfillment, kit assembly, labeling, packaging, shipping, and quality control, as well as regulatory and quality management support and equipment storage and maintenance. Bluejay also furnished a related press release as an exhibit.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
| (State or Other Jurisdiction of Incorporation or Organization) | (Commission File No.) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices and zip code)
(
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01 Entry into a Material Definitive Agreement.
On October 3, 2025, Bluejay Diagnostics, Inc. (the “Company”) entered into an agreement (the “Amendment”) to amend its Master Service Agreement and the Master Supply Agreement with Sanyoseiko Co., Ltd. (“Sanyoseiko”). The Amendment was entered into in connection with Bluejay expanding SanyoSeiko’s role in helping to commercialize Bluejay’s Symphony platform, a near-patient testing system designed to provide rapid and reliable results for key biomarkers such as IL-6 in sepsis management.
Pursuant to statements of work that the Company has begun to Sanyoseiko under these agreements, as amended by the Amendment, Sanyoseiko will provide end-to-end support for the Symphony platform, including supporting the manufacturing redevelopment process for analyzers and cartridges (with hardware, software, and design updates), managing raw material sourcing and vendor compliance, and serving as the Company’s contract manufacturing organization for analyzers, cartridges, and related components. In this capacity, Sanyoseiko will oversee fulfillment, kit assembly, labeling, packaging, shipping, and quality control of manufactured products, while also providing regulatory and quality management support, and equipment storage and maintenance.
The foregoing descriptions of the Master Service Agreement, the Master Supply Agreement and the Amendment do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements, which are filed as Exhibit 10.1, 10.2 and 10.3, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
On October 9, 2025, the Company issued a press release in connection with the matters discussed herein under item 1.01. A copy of that press release is furnished with this report as Exhibit 99.1.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| 10.1 | Master Supply Agreement dated July 30, 2021, between Bluejay Diagnostics, Inc. and Sanyoseiko Co., Ltd. | |
| 10.2 | Master Service Agreement dated July 30, 2021, between Bluejay Diagnostics, Inc. and Sanyoseiko Co., Ltd. | |
| 10.3 | Agreement to Amend Master Supply Agreement and Master Service Agreement, dated October 3, 2025, between Bluejay Diagnostics, Inc. and Sanyoseiko Co., Ltd. | |
| 99.1 | Press Release, dated October 9, 2025. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Bluejay Diagnostics, Inc. | ||
| By: | /s/ Neil Dey | |
| Neil Dey | ||
| President and Chief Executive Officer | ||
Date: October 9, 2025
2
FAQ
What did Bluejay Diagnostics (BJDX) announce in this Form 8-K?
Bluejay Diagnostics reported that on October 3, 2025 it entered into an agreement to amend its existing Master Service Agreement and Master Supply Agreement with Sanyoseiko Co., Ltd.. The amendment is connected to expanding Sanyoseiko’s role in helping commercialize Bluejay’s Symphony near-patient testing platform.
How is Sanyoseiko’s role changing under the amended agreements with BJDX?
Under the amended agreements, Sanyoseiko will provide end-to-end support for the Symphony platform. This includes supporting manufacturing redevelopment for analyzers and cartridges, managing raw material sourcing and vendor compliance, serving as contract manufacturer for analyzers, cartridges and related components, and overseeing fulfillment, kit assembly, labeling, packaging, shipping, and quality control.
What is Bluejay Diagnostics’ Symphony platform mentioned in the filing?
The Symphony platform is described as a near-patient testing system designed to provide rapid and reliable results for key biomarkers such as IL-6, which can be used in sepsis management. The amended agreements with Sanyoseiko are intended to support commercialization of this platform.
What additional support will Sanyoseiko provide to Bluejay Diagnostics?
Beyond manufacturing, Sanyoseiko will provide regulatory and quality management support, and equipment storage and maintenance. It will also oversee fulfillment-related activities, including kit assembly, labeling, packaging, shipping, and quality control of manufactured Symphony products.
Did Bluejay Diagnostics issue a press release about the Sanyoseiko amendment?
Yes. The company states that on October 9, 2025 it issued a press release regarding the matters discussed in Item 1.01. A copy of this press release is furnished as Exhibit 99.1 to the report, and the information in Item 7.01 and Exhibit 99.1 is furnished rather than filed under the securities laws.
Which key exhibits are included with this Bluejay Diagnostics 8-K?
The exhibits listed include: 10.1 Master Supply Agreement dated July 30, 2021; 10.2 Master Service Agreement dated July 30, 2021; 10.3 Agreement to Amend those agreements dated October 3, 2025, all between Bluejay Diagnostics, Inc. and Sanyoseiko Co., Ltd.; 99.1 the related press release dated October 9, 2025; and 104 the cover page interactive data file.
